Long-term use of progestogens – effects on endometriosis, adenomyosis and myomas

References

• Hammond C B, Haney A F. Conservative treatment of endometriosis. Fertil Steril 1978; 30: 497–509
   PubMed Web of Science ®Google Scholar
• Kauppila A, Rönnberg L, Viehko R. Steroidrezeptoren in endometrischem. Gewebe Endometriose 1986; 4: 56–59
   Google Scholar
• Vierikko P, Kauppila A, Rönnberg L, Viehko R. Steroidal regulation of endometriosis tissue. Fertil Steril 1985; 43: 218–223
   PubMed Web of Science ®Google Scholar
• Obolensky W, Kamber J. Therapie der Endometriose mit Dydrogesteron in Depot form. Ther Umsch 1973; 30: 558–562
   PubMedGoogle Scholar
• Schweppe K-W. Klinik und Morphologie der Endometriose. Schattauer, Stuttgart 1984; 133–150
   Google Scholar
• Zeitoun K M, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Putman M, Carr B, Bulun S E. Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis. Failure to metabolize 17β-estradiol. J Clin Endocrinol Metab 1998; 83: 4474–4478
   PubMed Web of Science ®Google Scholar
• Attar E, Bulun S E. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Human Reprod Update 2006; 12: 49–56
   PubMed Web of Science ®Google Scholar
• Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor α-induced interleukin-8 production via nuclear factor κB inactivation in endometriotic stromal cells. Fertil Steril 2005; 83: 1530–1535
   PubMed Web of Science ®Google Scholar
• Timmonen S, Johansson C J. Endometriosis treated with lynestrenol. Ann Chir Gynaecol 1968; 57: 144–147
   Google Scholar
• Andrews M C, Andrews W C, Strauss A F. Effects of progestin induced pseudopregnancy on endometriosis: clinical and microscopic studies. Am J Obstet Gynecol 1959; 78: 776
   PubMed Web of Science ®Google Scholar
• Seliger E, Kaltwasser P, Schneider F, Rothe K, Röpke F. Behandlung der Endometriose mit Dienogest – Einfluss auf den Rezeptorstatus im Endometrium und vergleichende Bindungsstudien. Dienogest – Präklinik und Klinik eines Gestagens, A T Teichmann. W. de Gruyter Verlag, Berlin 1995; 231–243
   Google Scholar
• Telimaa S, Puolakka J, Rönnberg I, Kauppila A. Placebo controlled comparison of danazol and high dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987; 1: 13–19
   PubMedGoogle Scholar
• Schweppe K-W. Einsatz der Gestagene zur Behandlung der Endometriose – Medrogeston versus Danazol. Menopause aktuell, A E Schindler, Ch Ebert. Aesopus, Basel 1996; 85–93
   Google Scholar
• Vercellini P, Trespidi L, Vendola N. A gonadotropin releasing hormone agonist versus a low dose OC for pelvic pain associated with endometriosis. Fertil Steril 1993; 60: 75–79
   PubMed Web of Science ®Google Scholar
• Regidor P A, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, Kienle E, Schindler A E. Prospective randomised study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol 2000; 14: 1–8
   PubMed Web of Science ®Google Scholar
• Lockhat F B, Emembolu J O, Konje J C. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod 2005; 20: 789–793
   PubMed Web of Science ®Google Scholar
• Schweppe K-W. GnRH analogues: state of the art. GnRH analogues, B Lunenfeld, V Insler. Parthenon Publishing Group, CarnforthUK 1996; 83–94
   Google Scholar
• Vercellini P, Cortesi I, Crosignani P G. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68: 393–401
   PubMed Web of Science ®Google Scholar
• Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod Update 1998; 4: 323–336
   PubMed Web of Science ®Google Scholar
• Buttram V C, Reiter R S. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 1981; 36: 433–442
   PubMed Web of Science ®Google Scholar
• Townsend D E, Sparkes R S, Baluda M C, McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970; 107: 1168–1173
   PubMed Web of Science ®Google Scholar
• Nibert M, Heim S. Uterine leiomyoma cytogenetics. Genes Chromosomes Cancer 1990; 2: 3–13
   PubMedGoogle Scholar
• Rein M S, Friedman A J, Barbieri R L. Cytogenic abnormalities in uterine leiomyomata. Obstet Gynecol 1991; 77: 923–926
   PubMed Web of Science ®Google Scholar
• Rein M S, Barbieri R L, Friedman A J. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995; 172: 14–18
   PubMed Web of Science ®Google Scholar
• Kawaguchi D, Fujii S, Konishi I, Nanbu Y, Nonagaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989; 160: 637–641
   PubMed Web of Science ®Google Scholar
• Amminen S, Rantala I, Helin H, Rorarius M, Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest 1992; 34: 111–114
   PubMedGoogle Scholar
• Harrison-Woolrych M L, Charnock-Jones D S, Smith S K. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction. J Clin Endocrinol Metab 1994; 78: 1179–1184
   PubMed Web of Science ®Google Scholar
• Brandon D D, Bethea C L, Strawn E Y. Progesterone receptor messenger ribonucleic acid and protein are over expressed in human uterine leiomyomas. Am J Obstet Gynecol 1993; 169: 78–85
   PubMed Web of Science ®Google Scholar
• Buchi K A, Keller P J. Cytoplasmic progestin receptors in myomal and myometrial tissues. Concentrations and hormonal dependency. Acta Obstet Gynecol Scand 1983; 62: 487–492
   PubMedGoogle Scholar
• Vij U, Murugesan K, Laumas K R, Farooq A. Progestin and antiprogestin interactions with progesterone receptors in human myomas. Int J Gynaecol Obstet 1990; 31: 347–353
   PubMed Web of Science ®Google Scholar
• Segaloff A, Weed J C, Sternberg W H, Parson W. The progesterone therapy of human uterine leiomyomas. J Clin Endocrinol Metab 1949; 9: 1273–1291
   PubMedGoogle Scholar
• Mixson W T, Hammond D O. Response of fibromas to a progestin. Am J Obstet Gynecol 1961; 82: 754–760
   PubMed Web of Science ®Google Scholar
• Maheux R. Treatment of fibroids with the combination of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. Advances in reproductive endocrinology: Uterine fibroids, time for review, R W Shaw. Parthenon Publishing Group, CarnforthUK 1992; 135–146
   Google Scholar